Previous close | 234.36 |
Open | 232.33 |
Bid | 232.58 x 1100 |
Ask | 232.87 x 1100 |
Day's range | 230.02 - 233.04 |
52-week range | 229.40 - 287.32 |
Volume | |
Avg. volume | 1,356,033 |
Market cap | 67.17B |
Beta (5Y monthly) | 0.46 |
PE ratio (TTM) | 53.33 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 3.80 (1.62%) |
Ex-dividend date | 07 Mar 2024 |
1y target est | N/A |
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will receive the Business Group on Health "Best Employers: Excellence in Health & Well-being Award" for its commitment to advancing employee well-being through comprehensive and innovative benefits and initiatives.
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the global commercial release of new cell sorters that will enable more researchers in a broader range of fields, including cell biology, cancer research and immunology, to reveal insights that were previously invisible in traditional flow cytometry experiments.
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will report financial results for its second quarter of fiscal year 2024 on Thursday, May 2, 2024. A news release will be issued at approximately 6:30 a.m. Eastern Time (ET) and will be available at www.bd.com/investors, along with related presentation materials. The news release and presentation materials will include summary financial information for the company's second quarter